GlassScriptPhysician profile
Evelyn Batres
NPI 1053076596
$6,412.29
in general payments reported to CMS, 2019-2025
31 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $398 · 2023: $2,444 · 2024: $1,581 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,950 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,949.64 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,308.97 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $739.23 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $709.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $578.15 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $513.71 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $304.08 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $298.48 | 2022-2025 | |
| Ardelyx, INC. | $245.17 | 2024-2025 | Ibsrela |
| Evoke Pharma, INC. | $219.80 | 2023 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.02 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $197.72 | 2022-2025 | |
| Amgen INC. | $151.50 | 2022-2025 | Repatha, Otezla, Otezla |
| Sumitomo Pharma America, INC. | $102.59 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $86.74 | 2022-2025 | Verquvo, Steglatro |
| Shield Therapeutics INC | $76.03 | 2023-2025 | Accrufer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $75.01 | 2024-2025 | Zenpep |
| Pfizer INC. | $67.60 | 2023-2024 | |
| Lilly USA, LLC | $65.63 | 2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $64.95 | 2023 | |
| Exact Sciences Corporation | $64.24 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.98 | 2022-2025 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $54.49 | 2023 | Linzess |
| Cumberland Pharmaceuticals, INC. | $42.76 | 2025 | Kristalose |
| Corcept Therapeutics | $40.93 | 2022 | |
| Dexcom, INC. | $21.39 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $20.45 | 2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $20.00 | 2023 | |
| Baxter Healthcare | $19.35 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Ibsa Pharma INC. | $18.52 | 2022 | |
| Redhill Biopharma INC. | $18.39 | 2022 | |
| Mylan Specialty L.P. | $17.38 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Batres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.